Home › Funds › Persistent Asset Partners Ltd › FDMT

Persistent Asset Partners Ltd position in FDMT

4D MOLECULAR THERAPEUTICS IN · Health Care

Persistent Asset Partners Ltd reported holding 106,954 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.57% of its reported portfolio and ranking #28 among its reported holdings. Persistent Asset Partners Ltd has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)106.95K sh
Reported value held$1.53M
Portfolio Weight0.57%
First reportedQ2 2026
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Persistent Asset Partners Ltd's FDMT position evolved

Persistent Asset Partners Ltd first disclosed a stake in FDMT in Q2 2026 at 145,585 shares (US$1.9M). Across 2 filings, Persistent Asset Partners Ltd increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 106,954 shares valued at US$1.5M — a reduction of -38,631 shares quarter over quarter.. Notable position changes include a 27% trim in Q3 2026 (shares fell 15% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 145.59K $1.94M New
Q3 2026 106.95K $1.53M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FDMT and 13F data

FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 38 other funds we track also report a position in FDMT — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.2M), Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FDMT

All FDMT fund holders →

FAQ

How long has Persistent Asset Partners Ltd held FDMT?

Persistent Asset Partners Ltd has disclosed FDMT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Persistent Asset Partners Ltd's current position in FDMT?

As of Q3 2026, Persistent Asset Partners Ltd holds 106.95K shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $1.53M, representing 0.57% of its reported portfolio and ranking #28.

Has Persistent Asset Partners Ltd been buying or selling FDMT?

In the latest 13F filing (Q3 2026), Persistent Asset Partners Ltd reduced its position in FDMT.

Which other funds hold FDMT?

Other major institutional holders of FDMT include RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, BVF INC/IL, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.